Association between depression and metabolic dysfunction-associated fatty liver disease/significant fibrosis
Journal of Affective Disorders · 2023-05 · 329 · 184-191
DOI: 10.1016/j.jad.2023.02.101 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Affective Disorders, 2023-05. Verfasst von Donghee Kim und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA, United States. Electronic address: dhkimmd@stanfor…. Hauptthemen laut MEDLINE: Depression, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 42 Literaturangaben.
Themen: Depression
Abstract (Originalsprache)
BACKGROUND: An association between depression and metabolic dysfunction-associated fatty liver disease (MAFLD) appears logical on the basis of previous observations linking depression to nonalcoholic fatty liver disease. We aim to investigate the association between depression and MAFLD and significant fibrosis. METHODS: This cross-sectional study was conducted on data from National Health and Nutrition Examination Survey, 2017 to March 2020 Pre-pandemic dataset. Depression and depression-related functional impairment were assessed using the Patient Health Questionnaire (PHQ-9). MAFLD, based on the criteria proposed by an international expert panel, and significant fibrosis were defined by transient elastography. RESULTS: Of the 3327 individuals (mean age: 46.9 years, 50.2 % men), the prevalence of depression and functional impairment due to depression was higher among individuals with MAFLD or significant fibrosis than among those without. Individuals with depression were approximately 70 % more likely to have MAFLD than those without. In multivariable analyses, depression was associated with an increased risk of MAFLD (odds ratio [OR]: 1.77, 95 % confidence interval [CI]:1.33-2.36 for ≥263 dB/m and OR: 1.70, 95 % CI: 1.20-2.41 for ≥285 dB/m). These associations were more pronounced in postmenopausal women than premenopausal women. In terms of significant fibrosis, depression remained an independent predictor of significant fibrosis; however, it attenuated after adjustment for body mass index. LIMITATIONS: Temporal causality and residual confounders could not be entirely investigated due to the study design. CONCLUSIONS: Depression was independently associated with MAFLD and significant fibrosis in a nationally representative sample of adults in the US.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA, United States. Electronic address: dhkimmd@stanford.edu.
- British Columbia Centre on Substance Use, University of British Columbia, Vancouver, Canada.
- Liver Center, Division of Abdominal Transplantation, Michael E DeBakey Department of General Surgery, Baylor College of Medicine, Houston, TX, United States; Section of Gastroenterology and Hepatology, Department of Med…
- Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA, United States. Electronic address: aijazahmed@stanford.edu.
Zitieren
APA
Kim, D., Dennis, B. B., Cholankeril, G., & Ahmed, A. (2023). Association between depression and metabolic dysfunction-associated fatty liver disease/significant fibrosis. Journal of Affective Disorders, 329, 184-191. https://doi.org/10.1016/j.jad.2023.02.101
Vancouver
Kim D, Dennis BB, Cholankeril G, Ahmed A. Association between depression and metabolic dysfunction-associated fatty liver disease/significant fibrosis. Journal of Affective Disorders. 2023;329:184-191. doi:10.1016/j.jad.2023.02.101
BibTeX
@article{Kim2023,
author = {Kim, Donghee and Dennis, Brittany B and Cholankeril, George and Ahmed, Aijaz},
title = {Association between depression and metabolic dysfunction-associated fatty liver disease/significant fibrosis},
journal = {Journal of Affective Disorders},
year = {2023},
volume = {329},
pages = {184--191},
doi = {10.1016/j.jad.2023.02.101}
}
EUVIMED